利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.033 秒)

    IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS
    2.
    发明授权
    IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS 有权
    Imidazopyrimidines和三唑：苯二氮卓受体配体

    公开(公告)号：EP1648899B1

    公开(公告)日：2007-01-03

    申请号：EP04779031.6

    申请日：2004-07-23

    申请人： NEUROGEN CORPORATION

    发明人： XIE, Linghong ,  HAN, Bingsong ,  XU, Yuelian ,  MAYNARD, George ,  CHENARD, Bertrand, L. ,  SHAW, Kenneth ,  GAO, Yang

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04

    摘要： Compounds of Formula (I) are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

    TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES
    3.
    发明公开
    TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES 审中-公开
    四氢吡啶[3,4-D]嘧啶及其类似物

    公开(公告)号：EP2029588A2

    公开(公告)日：2009-03-04

    申请号：EP07795899.9

    申请日：2007-06-08

    申请人： NEUROGEN CORPORATION

    发明人： XU, Yuelian ,  GAO, Yang ,  XIE, Linghong

    IPC分类号： C07D471/02 ,  C07D417/14 ,  C07D265/30 ,  A61K31/54

    CPC分类号： A61K31/496 ,  A61K31/55 ,  C07D471/04 ,  C07D487/04

    摘要： Tetrahydropyrido[3,4-d]pyrimidines and related analogues are provided, of the formula (I) in which variables are as described herein, as are methods for their preparation and use. Such compounds may generally be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and therapeutic methods are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

    摘要翻译： 提供了式（I）的四氢吡啶并[3,4-d]嘧啶及相关类似物，其中变量如本文所述，以及它们的制备和使用方法。 这些化合物通常可以用于在体内或体外调节配体与组胺H3受体的结合，并且特别可用于治疗人，家养伴侣动物和家畜动物中的各种病症。 提供了药物组合物和治疗方法，以及使用这些配体检测组胺H3受体的方法（例如受体定位研究）。

    THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES
    5.
    发明公开
    THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES 审中-公开
    噻唑酰胺，咪唑酰胺和相关类似物

    公开(公告)号：EP1848428A2

    公开(公告)日：2007-10-31

    申请号：EP06735288.0

    申请日：2006-02-16

    申请人： NEUROGEN CORPORATION

    发明人： PRINGLE, Wallace C. ,  PETERSON, John M. ,  XIE, Linghong ,  GE, Ping ,  GAO, Yang ,  OCHTERSKI, Joseph W. ,  LAN, Jiong

    IPC分类号： A61K31/426 ,  C07D277/24 ,  C07D277/28

    CPC分类号： C07D231/14 ,  C07D233/64 ,  C07D233/90 ,  C07D277/28 ,  C07D277/30 ,  C07D401/06 ,  C07D403/06 ,  C07D417/04 ,  C07D417/06 ,  C07D417/12 ,  C07D417/14 ,  C07D451/04 ,  C07D471/04

    摘要： Thiazole amides, imidazole amides and related analogues of the Formula: are provided, in which variables are as described herein. Such compounds may be used to modulate ligand binding to histamine H3 receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) and other disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting histamine H3 receptors (e.g., receptor localization studies).

    摘要翻译： 提供噻唑酰胺，咪唑酰胺和式的相关类似物，其中变量如本文所述。 此类化合物可用于在体内或体外调节配体与组胺H3受体的结合，并且特别用于治疗人类，家养伴侣动物和家畜动物中的各种中枢神经系统（CNS）和其他病症。 本文提供的化合物可以单独施用或与一种或多种其他CNS试剂组合施用以增强其他CNS试剂的作用。 提供了用于治疗此类病症的药物组合物和方法，以及使用这些配体检测组胺H3受体的方法（例如受体定位研究）。

    PYRAZOLYLMETHYL HETEROARYL DERIVATIVES
    7.
    发明公开
    PYRAZOLYLMETHYL HETEROARYL DERIVATIVES 审中-公开
    吡唑基，HETEROARYLDERIVATE

    公开(公告)号：EP1807417A2

    公开(公告)日：2007-07-18

    申请号：EP05825135.6

    申请日：2005-11-01

    申请人： NEUROGEN CORPORATION

    发明人： XU, Yuelian ,  XIE, Linghong ,  GAO, Yang ,  HAN, Bingsong ,  MAYNARD, George, D. ,  CHENARD, Bertrand, L. ,  LAN, Jiong

    IPC分类号： C07D401/14 ,  C07D403/14 ,  C07D231/28

    CPC分类号： G01N33/9426 ,  C07D401/14 ,  C07D417/14 ,  C07D487/04

    摘要： Compounds of Formula (I) are provided, as are methods for their preparation. The variables W, X, Y, Z, R5, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).

    IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS
    10.
    发明公开
    IMIDAZO-PYRIMIDINES AND TRIAZOLO-PYRIMIDINES: BENZODIAZEPINE RECEPTOR LIGANDS 有权
    Imidazopyrimidines和三唑：苯二氮卓受体配体

    公开(公告)号：EP1648899A2

    公开(公告)日：2006-04-26

    申请号：EP04779031.6

    申请日：2004-07-23

    申请人： NEUROGEN CORPORATION

    发明人： XIE, Linghong ,  HAN, Bingsong ,  XU, Yuelian ,  MAYNARD, George ,  CHENARD, Bertrand, L. ,  SHAW, Kenneth ,  GAO, Yang

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04

    摘要： Compounds of Formula (I) are provided, as are methods for their preparation. The variables Z1, Z2, Z3, R4, R5, R6, R7, R8 and Ar in the above formula are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g., receptor localization studies).